Esperion Therapeutics (NASDAQ:ESPR) Stock Rating Upgraded by Wall Street Zen

Esperion Therapeutics (NASDAQ:ESPR) was upgraded by research analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a report issued on Saturday.

Other equities analysts have also issued research reports about the company. Citigroup reissued a “market outperform” rating on shares of Esperion Therapeutics in a research report on Wednesday, November 12th. HC Wainwright reissued a “buy” rating and set a $16.00 price target on shares of Esperion Therapeutics in a report on Friday, September 19th. Weiss Ratings restated a “sell (d-)” rating on shares of Esperion Therapeutics in a report on Wednesday, October 8th. Piper Sandler began coverage on Esperion Therapeutics in a research report on Tuesday, November 25th. They set an “overweight” rating and a $9.00 price objective on the stock. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Esperion Therapeutics in a research note on Wednesday, November 12th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $7.20.

Esperion Therapeutics Price Performance

Shares of ESPR opened at $3.71 on Friday. The company has a 50-day simple moving average of $3.44 and a two-hundred day simple moving average of $2.52. The firm has a market capitalization of $886.91 million, a PE ratio of -7.42, a price-to-earnings-growth ratio of 11.36 and a beta of 1.04. Esperion Therapeutics has a one year low of $0.69 and a one year high of $4.13.

Esperion Therapeutics (NASDAQ:ESPR) last announced its earnings results on Thursday, November 6th. The biopharmaceutical company reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.07). The firm had revenue of $87.31 million for the quarter, compared to analysts’ expectations of $78.33 million. Analysts expect that Esperion Therapeutics will post -0.29 EPS for the current fiscal year.

Insider Transactions at Esperion Therapeutics

In other Esperion Therapeutics news, CFO Benjamin Halladay sold 7,337 shares of the company’s stock in a transaction that occurred on Wednesday, December 17th. The stock was sold at an average price of $3.67, for a total value of $26,926.79. Following the sale, the chief financial officer owned 467,525 shares in the company, valued at approximately $1,715,816.75. This represents a 1.55% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. 1.70% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Esperion Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the business. DHJJ Financial Advisors Ltd. raised its holdings in Esperion Therapeutics by 209.2% in the 3rd quarter. DHJJ Financial Advisors Ltd. now owns 9,430 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 6,380 shares during the period. North Star Investment Management Corp. purchased a new stake in Esperion Therapeutics during the 2nd quarter worth about $25,000. Sivia Capital Partners LLC acquired a new stake in Esperion Therapeutics during the second quarter worth approximately $25,000. Vanguard Personalized Indexing Management LLC purchased a new position in Esperion Therapeutics during the 3rd quarter worth approximately $29,000. Finally, R Squared Ltd purchased a new position in Esperion Therapeutics during the 3rd quarter worth $33,000. 47.39% of the stock is owned by hedge funds and other institutional investors.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of oral, low–density lipoprotein cholesterol (LDL-C)–lowering therapies. The company’s research and development efforts center on small-molecule compounds designed to address atherosclerotic cardiovascular disease by targeting cholesterol biosynthesis pathways. Esperion seeks to provide novel treatment options for patients who require additional LDL-C reduction beyond what is achieved with statins or who are statin-intolerant.

The company’s lead products include NEXLETOL (bempedoic acid), an oral adenosine triphosphate–citrate lyase (ACL) inhibitor approved by the U.S.